Acute Leukemia Forum 2009

 
 
 

Acute Leukemia Forum 2009 took place March 20, 2009, in San Francisco, California.

 

Partial HLA mismatch is tolerable in HSCT

Erilyn Riley Read Article
Published: 04/14/09

Bone marrow harvest
Bone marrow harvest

Transplants today are using better matched donors than ever before. In 2007, more than 60% of transplants had 8/8 matched donors, compared to a little over 40% in 1993. However, HLA-matched unrelated donors are found for only about half of patients who do not have an HLA-identical sibling. Mary M. Horowitz, MD, of the Medical College of Wisconsin and CIBMTR, explored, at Acute Leukemia Forum 2009 in March, how closely matched donors must be for optimal transplant outcomes. [Read Article]

The case for upping daunorubicin dose in induction

Erilyn Riley Read Article
Published: 04/13/09

Recent data on induction intensification in AML puts the standard of treatment in question, according to a presentation given at Acute Leukemia Forum 2009. Jacob M. Rowe, MD, of Technion, Israel Institute of Technology and Rambam Medical Center in Haifa, said 3 days of daunorubicin at 45 mg/m2 is no longer acceptable as induction therapy, though it has remained the standard against which most new regimens are tested. [Read Article]

Obstacles to progress in therapy for older AML patients

Bridget Wells Read Article
Published: 04/09/09

Bone marrow aspirate showing AML
Bone marrow aspirate
showing AML

There are several obstacles preventing improvements in therapy for the older patient with acute myeloid leukemia, according to a presentation at Acute Leukemia Forum 2009. At the March 20 meeting, Eli H. Estey, MD, of the University of Washington, discussed these obstacles and suggested some solutions to overcome them. [Read Article]

No best myeloablative regimen exists for AML

Bridget Wells Read Article
Published: 04/08/09

Frederick R. Appelbaum, MD
Frederick R. Appelbaum, MD

Despite adaptations and additions made to myeloablative conditioning regimens over the years, there is currently no superior one for acute myeloid leukemia, according to an expert in the field. At Acute Leukemia Forum 2009, Frederick R. Appelbaum, MD, of the Fred Hutchinson Cancer Research Center in Seattle, recounted how physicians have been modifying myeloablative regimens for the past 25 years but have yet to determine the best one. And trials have not aided the process because knowledge of patient and disease heterogeneity has outpaced clinicians’ ability to conduct randomized trials. [Read Article]

Revising the leukemia stem cell model

Erilyn Riley Read Article
Published: 04/07/09

Lab mouse
Lab mouse

Recent research advances have rendered the original model of the leukemia stem cell (LSC) out-of-date, according to a presenter at Acute Leukemia Forum 2009. The original model was based on xenotransplant studies of acute myeloid leukemia and proposed that leukemic hematopoiesis is a caricature of normal hematopoiesis. In a talk at the March 20 meeting, Michael L. Cleary, MD, of Stanford School of Medicine, proposed a revised and updated model of the LSC based on newer evidence. [Read Article]

Several mutations play different roles in MPNs

Bridget Wells Read Article
Published: 04/06/09

Bone marrow specimen showing polycythemia vera
Bone marrow specimen
showing polycythemia vera

Investigators have known for several years that JAK2 mutations play a key role in many myeloproliferative neoplasms (MPNs), but some basic questions about these and other mutations in MPNs remain unanswered. Ross L. Levine, MD, of Memorial Sloan-Kettering Cancer Center, reviewed recent findings and shed some light on the mechanisms of MPN mutations at Acute Leukemia Forum 2009, which took place March 20. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}